|
| Status |
Public on Apr 21, 2017 |
| Title |
Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate for Alopecia Areata and Variants |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
The samples include RNA from scalp biopsies before treatment and at 8 weeks of treatment with Tofacitinib Citrate 5 mg BID in patients with Alopecia Areata. 32% had a SALT score of 50% or higher and 47% had clinically significant response.
|
| |
|
| Overall design |
Open label trial of patients with Alopecia Areata of more than 6 months in duration refractory to standard therapy. Each patient took tofacitinib citrate 5mg BID for 3 months and then stopped. Biopsies were taken pretreatment and then at 8 weeks from the scalp and submitted for RNA sequencing.
|
| |
|
| Contributor(s) |
Oro A, Shankar G |
| Citation(s) |
27699252 |
| Submission date |
Apr 26, 2016 |
| Last update date |
Sep 16, 2019 |
| Contact name |
Anthony Oro |
| E-mail(s) |
oro@stanford.edu
|
| Organization name |
Stanford University
|
| Department |
Dermatology
|
| Lab |
Oro
|
| Street address |
269 Campus Drive, CCSR 2145c
|
| City |
Stanford |
| State/province |
CA |
| ZIP/Postal code |
94305 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
| Samples (56)
|
|
| Relations |
| BioProject |
PRJNA319674 |
| SRA |
SRP073940 |
Less...
More...